Biotechnology company Emyria (ASX: EMD), which develops treatments for mental health and neurological conditions, has newly inaugurated its treatment facility Empax Centre. The centre has been selected as a key site for a clinical trial sponsored by New York-based Transcend Therapeutics. The trial will evaluate the safety and efficacy of methylone, a novel rapid-acting neuroplastogen
Read More
Mental health treatment provider Emyria (ASX: EMD) has announced that its psychiatry specialist has been granted “Authorised Prescriber” status by the Therapeutic Goods Administration (TGA). The authorisation enables the prescribing of MDMA according to an ethics committee endorsed care model developed by Emyria and within the strict regulatory framework established by the TGA for the
Read More
Although it doesn’t apply to me, many of you may remember the early mornings during adolescence when you were throwing yourself around in a club, parading a locked-jaw, and beaming pupils so wide it would be hard to deny that you weren’t on something. Well, chances are, you had consumed MDMA, or if you were
Read More
If you read my articles often, you would know that I can become quite laudatory when discussing small cap companies excelling in recreational drug regulation and using once illegal drugs to treat various mental health conditions and illnesses. Ranging from cannabis to psychedelics, and now, MDMA. Most of my articles surrounding this area follow the
Read More
Harbouring more MDMA than music festival goers, the University of Western Australia (UWA) is leading the way in research around the use of MDMA as a psychedelic medication. Clinical drug development and care delivery company Emyria (ASX: EMD) has today announced a partnership with UWA, confirming access to their library of MDMA- like compounds developed
Read More
Pharmaceuticals company Emyria (ASX: EMD) is set to commence the regulatory process of registering their cannabinoid-based medicine EMD-003 as a treatment to reduce symptoms of mental health disorders, leveraging extensive data gathered from their network of clinics. Initial evidence collected by Emyria’s subsidiary Emerald Clinics has identified an unmet need by targeting the treatment of
Read More